A current article in the journal Nature Communications provides some real hope that there may be a way to selectively target cancer cells. This article, entitled "Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease" describes work done by scientists at Stony Brook University in New York. These scientists found that all the cancer cells that they tested had high levels of two enzymes, histone deacetylase (HDAC) and a protease called cathepsin L (CTSL).
|Space-filling model of puromycin, an antibiotic|
A similar approach could revive other compounds that were deemed too cytotoxic for clinical use.